J. Goldman & Co’s Axsome Therapeutics AXSM Stock Holding History

J. Goldman & Co’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-6,800	Closed	-$1.24M	–	672
2025 Q4	$1.24M	Buy	+6,800	New	+$949K	0.03%	360

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

J. Goldman & Co's AXSM Position: Q4 2025 in Review

J. Goldman & Co sold out of Axsome Therapeutics (AXSM) in Q4 2025, closing a stake of 8,401 shares — an estimated $1.17M sold.

J. Goldman & Co first reported a position in AXSM in Q1 2019 and held it in 16 quarters. The position peaked at $4.14M in Q2 2025. 398 funds tracked by Wall St. Rank hold AXSM as of Q4 2025.

J. Goldman & Co reported no remaining Axsome Therapeutics position as of Q4 2025 after selling out during the quarter.
J. Goldman & Co sold 8,401 Axsome Therapeutics shares in Q4 2025, an estimated $1.17M.
J. Goldman & Co first reported a position in Axsome Therapeutics in Q1 2019 and held it in 16 quarters.
J. Goldman & Co's Axsome Therapeutics position peaked at $4.14M in Q2 2025.
398 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2025.

Based on J. Goldman & Co's 13F filing for Q4 2025, filed 17 Feb 2026.